Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant

PDF) A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma

Nivolumab plus ipilimumab shows benefit in advanced prostate cancer subset

Treatments

Metastatic castration resistant prostate cancer

Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial

PDF) Long-term complete remission with Ipilimumab in metastatic castrate- resistant prostate cancer: Case report of two patients

Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial

Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial - The Lancet Oncology

Castration-resistant prostate cancer: latest evidence and therapeutic implications - Daniel L. Suzman, Emmanuel S. Antonarakis, 2014

ASCO GU 2019: Initial Results from a Phase II Study of Nivolumab plus Ipilimumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer - CheckMate 650

Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial - ScienceDirect

Nivolumab: targeting PD-1 to bolster antitumor immunity

Cancers, Free Full-Text

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

Long-term complete remission with ipilimumab in metastatic castrate- resistant prostate cancer: case report of two patients